In vitro respiratory disease models play an important role in preclinical drug discovery by allowing researchers to investigate lung and airway biology under controlled experimental conditions. These models can help scientists explore disease mechanisms, evaluate candidate compounds and investigate how respiratory cells respond to inflammation, infection, injury and potential treatments.
For pharmaceutical and biotechnology companies, in vitro respiratory research can provide valuable evidence before or alongside more complex experimental studies. However, the usefulness of a model depends on how closely its biological characteristics match the research question.
Respiratory diseases involve interactions between multiple cell types, immune responses, tissue structures and physiological processes. No single in vitro system reproduces every aspect of a functioning human lung. Selecting the right model therefore requires a clear understanding of its capabilities, limitations and intended application.
This guide examines the main types of in vitro respiratory disease models, their uses in drug discovery, the endpoints researchers can investigate and the factors that influence their translational relevance.
What Are In Vitro Respiratory Disease Models?
In vitro respiratory disease models are experimental systems used to study lung or airway biology outside a whole living organism. They may use isolated cells, cultured tissues, three-dimensional structures or more complex systems designed to reproduce selected features of the respiratory environment.
Researchers use these models to investigate biological mechanisms and evaluate how potential treatments affect relevant cellular or tissue-level outcomes.
Depending on the scientific objective, an in vitro respiratory model may help answer questions such as:
- Does a candidate compound influence a specific inflammatory pathway?
- How do airway epithelial cells respond to an environmental or biological stimulus?
- Does a treatment affect cellular injury or viability?
- How does a respiratory virus interact with susceptible cells?
- Does a compound influence markers associated with fibrosis or tissue remodelling?
- Which candidate warrants further investigation in a more complex model?
The strength of an in vitro approach is its ability to examine particular mechanisms under controlled conditions. Its limitation is that cellular responses do not necessarily predict the behaviour of an entire organ or the clinical response of a patient.
The model should therefore be selected according to the question it is intended to answer, rather than treated as a complete representation of respiratory disease.
Why Are In Vitro Models Used in Respiratory Drug Discovery?
Respiratory drug development involves a broad range of biological targets and disease processes. In vitro models can provide focused evidence about these processes, helping researchers refine hypotheses and decide which candidates merit additional investigation.
Investigating Disease Mechanisms
Cell-based models allow researchers to investigate how particular pathways contribute to respiratory disease-associated processes.
For example, researchers may examine inflammatory signalling in airway epithelial cells, cellular responses to injury or changes in markers associated with tissue remodelling.
These experiments can help establish whether a proposed mechanism is biologically active in the selected system. They may also reveal differences between candidate compounds or identify questions that require further study.
Screening and Comparing Candidate Compounds
In vitro studies can support the early evaluation of multiple candidate compounds using predefined biological endpoints.
Depending on the model, researchers may assess cellular responses, inflammatory mediators, target-related activity or other measures relevant to the therapeutic hypothesis.
Screening results must be interpreted carefully. A compound that performs well in a simplified cellular system may behave differently in a more complex biological environment because of factors such as exposure, metabolism, tissue distribution and interactions between cell types.
In vitro screening is therefore most useful when its role in the wider development strategy is clearly defined.
Investigating Toxicity and Cellular Injury
Respiratory research may also investigate whether a compound produces unwanted cellular effects under the conditions tested.
Measures of cell viability, membrane integrity, cellular stress and other relevant endpoints can help characterise responses that may influence the interpretation of efficacy findings.
These assessments can provide early information, but they should not be confused with a comprehensive safety assessment. Results from a particular cell model do not establish the full safety profile of a candidate.
Supporting Mechanistic Research
In vitro systems can help distinguish between potential explanations for an observed biological effect.
For example, researchers may investigate whether a candidate’s activity is associated with a particular signalling pathway or whether the response appears alongside changes in cellular injury or inflammatory activity.
A carefully selected model and a focused set of endpoints can help generate evidence for or against the proposed mechanism. Additional experiments may still be required to establish causality or assess whether the mechanism is relevant in a more complex system.
Common Types of In Vitro Respiratory Disease Models
Different model types provide different levels of biological complexity. The appropriate choice depends on the disease process, cell types involved and intended application.
1. Airway Epithelial Cell Models
Airway epithelial cells form the surface lining of the respiratory tract and contribute to barrier function, mucociliary clearance and responses to environmental exposures and pathogens.
Airway epithelial cell models are commonly used to investigate inflammatory signalling, epithelial injury, barrier-associated processes and host responses to respiratory pathogens.
They can be useful when the research question concerns the direct effects of a compound or stimulus on airway epithelial biology.
However, a simple epithelial cell culture may not reproduce the full range of specialised cell types and interactions found in the human airway. Model characteristics also depend on the cell source, culture conditions and degree of differentiation.
Researchers should establish whether the selected system reproduces the specific epithelial features relevant to the study.
2. Primary Human Respiratory Cells
Primary human respiratory cells are obtained from human tissue or other appropriate biological sources and can provide a closer connection to human biology than some established cell lines.
Depending on the source and model, primary cells may be useful for investigating disease-associated responses, inflammatory mechanisms or the activity of potential respiratory treatments.
Their use also introduces practical considerations. Donor-to-donor variability, sample availability, cell condition and differences in culture behaviour can influence experimental outcomes.
Primary cells are not automatically more predictive in every application. Their value depends on the quality of the model, the question being asked and how variability is addressed in the study design.
3. Airway Models at Air-Liquid Interface
Air-liquid interface (ALI) cultures are designed to support airway epithelial cells under conditions that encourage differentiation and the development of features associated with the airway lining.
Depending on the system, these models may include mucus-producing cells, ciliated cells and barrier characteristics that are less readily represented in conventional submerged cell culture.
ALI models can be particularly useful for studying epithelial barrier biology, mucociliary function and interactions between respiratory pathogens and the airway surface.
They can also provide a more physiologically relevant environment for certain questions involving inhaled substances or airway exposures.
Nevertheless, ALI cultures do not reproduce the complete respiratory system. They may lack immune, vascular, neural and other components that influence disease behaviour in vivo.
4. Three-Dimensional Lung Models and Organoids
Three-dimensional models and organoids can provide more complex cellular arrangements than conventional two-dimensional cultures.
Depending on their design, they may help researchers investigate aspects of tissue organisation, cell differentiation and disease-associated changes in a more structured environment.
Their suitability varies considerably by model type. Different systems may represent specific airway or lung compartments, and their cellular composition and maturity can affect which biological questions they can address.
Researchers should assess what the model actually reproduces rather than assuming that three-dimensional architecture alone guarantees greater physiological relevance.
5. Co-Culture Models
Respiratory disease often involves communication between multiple cell types. Co-culture models introduce two or more cell populations to investigate selected interactions under controlled conditions.
For example, a study may examine interactions between epithelial cells and immune cells or investigate how one cell population influences inflammatory responses in another.
Co-culture systems can help answer questions that single-cell-type models cannot address adequately. However, the added complexity also creates additional variables that may influence interpretation.
The choice of cell populations, culture conditions and endpoints should be linked directly to the hypothesis being tested.
6. Lung-on-Chip and Microphysiological Systems
Lung-on-chip and related microphysiological systems aim to reproduce selected structural, mechanical or cellular features of respiratory tissues within engineered experimental platforms.
Some systems incorporate fluid flow, air exposure, mechanical forces or interactions between different cell compartments.
These approaches may be useful for questions involving tissue interfaces or processes that are difficult to represent in conventional cell culture.
However, the capabilities of individual platforms vary, and not every system reproduces every feature of lung physiology. Their value should be judged according to the biological processes represented, the quality of validation and the intended application.
In Vitro Models for Different Respiratory Diseases
The best model depends on the disease mechanism under investigation. Respiratory diseases are heterogeneous, and model selection should reflect the specific biological feature the study is designed to investigate.
Asthma Research
In vitro asthma research may focus on airway epithelial responses, inflammatory signalling, interactions with immune cells or mechanisms associated with airway dysfunction.
Cell-based systems can help investigate whether a candidate influences a defined pathway or modifies a cellular response associated with asthma biology.
However, asthma involves interactions between immune cells, airway smooth muscle, epithelium and other components of the respiratory environment. A single epithelial model cannot reproduce the entire disease phenotype.
In vitro findings are therefore most informative when interpreted within the context of the selected mechanism and supported by appropriate complementary evidence.
COPD Research
Chronic obstructive pulmonary disease involves multiple processes, including chronic inflammation, epithelial dysfunction and structural changes in the lungs.
In vitro COPD research may investigate cellular responses to relevant exposures, inflammatory signalling, oxidative stress or other mechanisms associated with the disease.
The suitability of the model depends on the specific question. A system designed to study epithelial responses may provide limited information about processes involving immune-cell recruitment, tissue destruction or whole-organ respiratory function.
Researchers should clearly define which component of COPD biology the model is intended to represent.
Pulmonary Fibrosis Research
Pulmonary fibrosis research often examines processes associated with abnormal tissue repair, extracellular matrix production and changes in cell behaviour.
In vitro systems can help investigate fibroblast activity, relevant signalling pathways and interactions between cells involved in fibrotic processes.
These models can provide useful mechanistic information, but fibrosis is influenced by complex interactions within lung tissue. A change in a fibrosis-associated marker in cultured cells does not independently demonstrate that a candidate will prevent or reverse fibrosis in an intact lung.
The model and endpoints should be selected to support a clearly defined conclusion.
Respiratory Infection Research
In vitro respiratory models can help researchers investigate interactions between pathogens and susceptible respiratory cells.
Depending on the system, studies may examine infection-associated cellular responses, inflammatory signalling, barrier changes or the activity of potential antiviral treatments.
Model suitability depends on factors such as the pathogen, target cell type, relevant biological process and endpoint. A model that supports one stage of a pathogen’s interaction with the host may not represent the full disease process.
Appropriate containment, validated procedures and relevant institutional requirements must also be considered when working with infectious agents.
Acute Lung Injury Research
Acute lung injury involves damage and inflammatory responses affecting the lung, including processes associated with the alveolar-capillary barrier.
In vitro models may be used to investigate cellular injury, barrier integrity and selected inflammatory mechanisms.
Such systems can help isolate specific processes, but they may not reproduce the interactions between epithelial cells, endothelial cells, immune responses and physiological forces present in the intact lung.
The interpretation should remain specific to the biological features represented by the model.
Choosing Endpoints for In Vitro Respiratory Studies
The value of an in vitro study depends partly on whether the selected endpoints provide meaningful evidence about the research question.
More measurements do not necessarily produce better evidence. A focused set of well-justified endpoints may be more informative than a large collection of markers with unclear relevance.
Cell Viability and Cellular Integrity
Cell viability and integrity measurements can help researchers determine whether a compound or stimulus produces cellular injury under the conditions tested.
These measurements are particularly important when interpreting apparent efficacy. A reduction in an inflammatory signal, for example, may be difficult to interpret if it occurs alongside substantial loss of viable cells.
The selected assays should be suitable for the model and should be interpreted alongside other relevant endpoints.
Inflammatory Mediators
Cytokines and other inflammatory mediators can provide information about cellular responses associated with respiratory disease.
Their usefulness depends on the biological pathway, cell type and experimental context. Changes in individual markers should not automatically be interpreted as evidence of broader disease modification.
Barrier Function
For airway epithelial and other relevant tissue models, barrier-associated measurements can help investigate the integrity of the cellular interface.
The most appropriate assessment depends on the model’s architecture and the specific barrier function being studied.
Researchers should confirm that the measurement reflects the biological feature of interest and that the assay is suitable for the experimental system.
Molecular and Pathway-Related Endpoints
Gene expression, protein measurements and other molecular endpoints can help investigate pathway activity or cellular responses to treatment.
The selection should be hypothesis-driven. Where possible, molecular findings should be interpreted alongside complementary functional or cellular measurements.
Evidence that a candidate changes a molecular marker is not necessarily evidence that the change produces a meaningful therapeutic effect.
Functional Cellular Responses
Some respiratory models support functional assessments related to their particular biological features, such as aspects of mucociliary activity or cellular responses to challenge.
The availability and relevance of these measurements vary by platform. Researchers should establish whether the endpoint is sufficiently validated and appropriate for the intended conclusion.
How to Assess the Translational Relevance of an In Vitro Model
Translational relevance describes how useful experimental findings may be for understanding human biology or informing subsequent development decisions.
No single characteristic establishes translational relevance. It depends on the combination of biological fidelity, experimental quality and relevance to the intended question.
Use a Model That Represents the Relevant Human Biology
Where possible, model selection should consider the origin of the cells, the features represented and the biological process being investigated.
Human-derived systems can be valuable for studying human-specific responses, but the use of human cells alone does not guarantee that the model accurately represents disease.
The model’s characteristics should be documented and evaluated against the research objective.
Consider Biological Variability
Human respiratory biology varies between individuals. Differences in donor characteristics, cell sources and culture behaviour can influence the results of in vitro experiments.
The study design should consider the sources of variability relevant to the model and the conclusions that can reasonably be drawn from the available data.
Understand the Limits of Simplified Systems
A simplified model can be highly useful for a focused mechanistic question. Its simplicity becomes a limitation when researchers attempt to draw conclusions about processes that the model does not represent.
For example, a monoculture may provide evidence about a cell-specific response but limited information about immune recruitment, tissue-level interactions or whole-organ function.
Recognising these boundaries improves the quality of interpretation.
Connect Findings to Complementary Evidence
Where justified, in vitro findings can be considered alongside evidence from other experimental systems, relevant published research and pharmacological information.
Different systems can address different uncertainties. The objective is not to force every result to agree, but to understand what each piece of evidence contributes to the overall assessment.
Common Challenges in In Vitro Respiratory Drug Discovery
Selecting a Model Before Defining the Research Question
A common design problem is choosing a familiar cell model before establishing the biological question.
This can result in endpoints that are easy to measure but do not adequately address the therapeutic hypothesis.
Defining the question first makes it easier to select the appropriate system and avoid collecting data that have limited decision-making value.
Treating Biomarker Changes as Proof of Efficacy
Changes in biomarkers can provide evidence of biological activity, but they do not necessarily establish therapeutic efficacy.
The interpretation should distinguish between pathway modulation, cellular effects and disease-relevant outcomes. Additional evidence may be needed to connect these levels of biological activity.
Ignoring Assay Interference
Some compounds can interfere with the analytical methods used to measure biological responses. This may create apparent changes that do not reflect the intended biological effect.
Assay suitability and potential interference should be considered when selecting measurement methods and interpreting results.
Overlooking Model-Specific Limitations
Different cell sources and culture systems can behave differently. Findings from one model should not automatically be assumed to apply to another.
Documenting the model’s characteristics and limitations helps researchers assess whether the evidence supports the intended conclusion.
Adding Complexity Without a Clear Benefit
More complex systems can represent additional biological features, but they may also introduce new variables and make interpretation more difficult.
The appropriate model is the one that provides the required evidence with sufficient reliability, not necessarily the most technologically advanced system available.
How In Vitro and In Vivo Respiratory Research Can Complement Each Other
In vitro and in vivo approaches provide different kinds of evidence and should not be treated as interchangeable.
In vitro systems are often valuable for focused mechanistic investigations, controlled comparisons and examining specific cellular responses. In vivo studies can provide information about integrated biological responses within an intact organism, although animal models also have important translational limitations.
A research programme may use in vitro findings to refine a hypothesis or identify candidates for further evaluation. Subsequent studies can then address questions that require a more complex biological system.
The appropriate sequence depends on the therapeutic mechanism, the uncertainty being addressed and the evidence already available.
An effective development strategy uses each model for the questions it can answer reliably, while avoiding conclusions that exceed the evidence.
Selecting an In Vitro Respiratory Research Partner
For biotechnology companies and pharmaceutical research teams, external expertise may be valuable when a project requires a particular cell model, specialised respiratory endpoint or experience with a defined disease mechanism.
When assessing a potential research partner, consider the following questions.
Model expertise: Can the team explain the biological characteristics and limitations of the proposed model?
Scientific rationale: Are the selected model and endpoints clearly connected to the research question?
Assay suitability: Are the measurements appropriate for the model, and have relevant limitations been considered?
Data interpretation: Can the team distinguish between cellular activity, pathway modulation and evidence of a disease-relevant effect?
Reporting quality: Will the methods, analysis and limitations be documented clearly enough to support subsequent decisions?
Integration with the wider programme: Can the proposed work address a defined uncertainty in the development strategy?
A suitable research partner should be able to explain not only what will be measured, but also why those measurements are relevant and what conclusions they can reasonably support.
Conclusion
In vitro respiratory disease models provide valuable tools for investigating lung and airway biology, evaluating candidate compounds and exploring mechanisms associated with respiratory disease.
From airway epithelial cell cultures and primary human cells to three-dimensional systems and lung-on-chip platforms, different approaches offer different levels of biological complexity. Their usefulness depends on the research question, the quality of the model and the relevance of the selected endpoints.
For respiratory drug discovery, the priority should be to choose a model that addresses a defined scientific objective, interpret findings within the limits of the system and use complementary evidence where needed.
A carefully designed in vitro study can help researchers refine hypotheses, characterise biological activity and make better-informed decisions about the next stages of preclinical respiratory drug development.